左氧氟沙星治疗难治性肺结核咯血的有效性和安全性meta分析

发布时间：2018-07-10 17:36

本文选题：左氧氟沙星 + 肺结核　；参考：《中国生化药物杂志》2014年07期

【摘要】：目的通过meta分析研究左氧氟沙星治疗难治性肺结核咯血的有效性和安全性。方法运用计算机检索Pubmed(2000/2014-07)、EMbase(2000/2014-07)、Cochrane图书馆(2014年第7期)、中国生物医学文献数据库(2000/2014-07)中关于左氧氟沙星治疗难治性肺结核咯血的随机对照试验,将检索时限定为2000年1月~2014年7月。经对检索到的论文进行客观的评价质量后,应用Cochrane协作网提供的Rev Man 5.3软件系统进行Meta分析。结果在6篇报道痰菌阴转率中,左氧氟沙星组较对照组明显增高,差异有统计学意义(OR=4.21,95%CI:3.08~5.75,P0.0001);对不良反应报道的3篇文章,均示实验组和对照组不良反应发生率无差异,无统计学意义(OR=0.82,95%CI:0.56~1.18,P=0.28)。结论采用左氧氟沙星对治疗难治性肺结核咯血临床疗效显著,安全性较高,对临床具有指导意义,值得临床推广。
[Abstract]:Objective to study the efficacy and safety of levofloxacin in the treatment of refractory pulmonary tuberculosis hemoptysis by meta analysis. Methods A randomized controlled trial of levofloxacin for refractory pulmonary tuberculosis hemoptysis was searched by computer in Pubmed (2000 / 2014-07) / EMbase (2000 / 2014-07) / Cochrane Library (issue 7, 2014), Chinese Biomedical Literature Database (2000 / 2014-07), and limited to January 2000 to July 2014. After an objective evaluation of the quality of the retrieved papers, Meta-analysis was carried out using the Rev Man 5.3 software system provided by the Cochrane Cooperative Network. Results the sputum negative conversion rate in levofloxacin group was significantly higher than that in control group (ORO 4.21% 95 CI: 3.085.75% P0.0001), and there was no difference in the incidence of adverse reactions between experimental group and control group. There was no statistical significance (OR 0.82 / 95 CI: 0.56 / 1.18 / P0. 28). Conclusion levofloxacin is effective and safe in the treatment of hemoptysis of refractory pulmonary tuberculosis.
【作者单位】：淮安第四人民医院结核科;
【基金】：卫生部医药科技发展研究中心项目(W2013R39)
【分类号】：R521

【参考文献】